An investor asked on the investor interaction platform: what is the planned annual production capacity of Nantong senxuan ritonavir intermediate project, a wholly-owned subsidiary of senxuan medicine?
Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) said on the investor interaction platform on January 11 that the planned annual production capacity of Nantong senxuan ritonavir series intermediates, a subsidiary of the company, is 230 tons.
(source: Daily Economic News)
